Modulation of cyclins, p53 and mitogen-activated protein kinases signaling in breast cancer cell lines by 4-(3,4,5-trimethoxyphenoxy)benzoic acid

International Journal of Molecular Sciences

Volumn 15, Issue 1, 2014, Pages 743-757

  Lee, Kuan Han ^a   Ho, Wen Yueh ^a   Wu, Shu Jing ^a   Omar, Hany A ^b,c   Huang, Po Jui ^d   Wang, Clay C C ^e   Hung, Jui Hsiang ^a  

^a CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

^b BENI SUEF UNIVERSITY   (Egypt)

^c UNIVERSITY OF SHARJAH   (United Arab Emirates)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

4 (3,4,5 trimethoxyphenoxy)benzoic acid; Apoptosis; Cyclins; MAPK kinases; MCF 7; MDA 468; p53

Indexed keywords

4 (3,4,5 TRIMETHOXYPHENOXY)BENZOIC ACID; 4', 6 DIAMIDINO 2 PHENYLINDOLE; ANTINEOPLASTIC AGENT; CASPASE 3; CYCLIN A; CYCLIN A1; CYCLIN B; CYCLIN B1; CYCLIN D2; CYCLIN DEPENDENT KINASE 1; CYCLIN E; CYCLINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MCL 1; PROTEIN P21; PROTEIN P53; PROTEIN TYROSINE PHOSPHATASE; SERINE; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TRYPAN BLUE; TYROSINE; UNCLASSIFIED DRUG; 4-(3,4,5-TRIMETHOXYPHENOXY)BENZOIC ACID; BENZOIC ACID DERIVATIVE; DIPHENYL ETHER DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER SUSCEPTIBILITY; CELL CYCLE ARREST; CELL DEATH; CELL STRUCTURE; CELL SURVIVAL; CELL VIABILITY; CHROMATIN; COLONY FORMATION; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IC 50; MODULATION; MTT ASSAY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; BREAST TUMOR; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HELA CELL LINE; HEPG2 CELL LINE; M PHASE CELL CYCLE CHECKPOINT; MCF 7 CELL LINE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SYNTHESIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOATES; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLINS; FEMALE; G2 PHASE CELL CYCLE CHECKPOINTS; HELA CELLS; HEP G2 CELLS; HUMANS; M PHASE CELL CYCLE CHECKPOINTS; MCF-7 CELLS; MITOGEN-ACTIVATED PROTEIN KINASES; PHENYL ETHERS; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84892180061     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms15010743     Document Type: Article

References (45)

1. Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin. 2011, 61, 69-90.
2. Abdellatif, K.R.A.; Belal, A.; Omar, H.A. Design, synthesis and biological evaluation of novel triaryl (Z)-olefins as tamoxifen analogues. Bioorg. Med. Chem. Lett. 2013, 23, 4960-4963.
3. Dupont, W.D.; Page, D.L. Risk factors for breast cancer in women with proliferative breast disease. N. E. J. Med. 1985, 312, 146-151.
4. Peshkin, B.N.; Alabek, M.L.; Isaacs, C. BRCA1/2 mutations and triple negative breast cancers. Breast Dis. 2010, 32, 25-33.
5. Wu, A.H.; Pike, M.C.; Williams, L.D.; Spicer, D.; Tseng, C.C.; Churchwell, M.I.; Doerge, D.R. Tamoxifen, soy, and lifestyle factors in Asian American women with breast cancer. J. Clin. Oncol. 2007, 25, 3024-3030.
6. Newcomb, P.A.; Kampman, E.; Trentham-Dietz, A.; Egan, K.M.; Titus, L.J.; Baron, J.A.; Hampton, J.M.; Passarelli, M.N.; Willett, W.C. Alcohol consumption before and after breast cancer diagnosis: Associations with survival from breast cancer, cardiovascular disease, and other causes. J. Clin. Oncol. 2013, 31, 1939-1946.
7. Abdelgawad, M.A.; Belal, A.; Omar, H.A.; Hegazy, L.; Rateb, M.E. Synthesis, anti-breast cancer activity, and molecular modeling of some benzothiazole and benzoxazole derivatives. Arch. Pharm. 2013, 346, 534-541.
8. Weng, J.R.; Omar, H.A.; Kulp, S.K.; Chen, C.S. Pharmacological exploitation of indole-3-carbinol to develop potent antitumor agents. Mini Rev. Med. Chem. 2010, 10, 398-404.
9. Johnstone, R.W.; Ruefli, A.A.; Lowe, S.W. Apoptosis: A link between cancer genetics and chemotherapy. Cell 2002, 108, 153-164.
10. Walczak, H.; Krammer, P.H. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp. Cell Res. 2000, 256, 58-66.
11. Ashkenazi, A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat. Rev. Cancer 2002, 2, 420-430.
12. Green, D.R.; Kroemer, G. The pathophysiology of mitochondrial cell death. Science 2004, 305, 626-629.
13. Saelens, X.; Festjens, N.; Vande Walle, L.; van Gurp, M.; van Loo, G.; Vandenabeele, P. Toxic proteins released from mitochondria in cell death. Oncogene 2004, 23, 2861-2874.
14. Degterev, A.; Boyce, M.; Yuan, J. A decade of caspases. Oncogene 2003, 22, 8543-8567.
15. Takimoto, R.; El-Deiry, W.S. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 2000, 19, 1735-1743.
16. Horn, H.F.; Vousden, K.H. Coping with stress: Multiple ways to activate p53. Oncogene 2007, 26, 1306-1316.
17. Tokino, T.; Nakamura, Y. The role of p53-target genes in human cancer. Crit. Rev. Oncol. Hematol. 2000, 33, 1-6.
18. Cheng, W.L.; Lin, T.Y.; Tseng, Y.H.; Chu, F.H.; Chueh, P.J.; Kuo, Y.H.; Wang, S.Y. Inhibitory effect of human breast cancer cell proliferation via p21-mediated G1 cell cycle arrest by araliadiol isolated from Aralia cordata Thunb. Planta Med. 2011, 77, 164-168.
19. Yoshida, K.; Miki, Y. The cell death machinery governed by the p53 tumor suppressor in response to DNA damage. Cancer Sci. 2010, 101, 831-835.
20. Ben Sahra, I.; Laurent, K.; Loubat, A.; Giorgetti-Peraldi, S.; Colosetti, P.; Auberger, P.; Tanti, J.F.; le Marchand-Brustel, Y.; Bost, F. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008, 27, 3576-3586.
21. Shah, M.A.; Schwartz, G.K. Cyclin-dependent kinases as targets for cancer therapy. Cancer Chemother. Biol. Response Modif. 2003, 21, 145-170.
22. Gillett, C.; Fantl, V.; Smith, R.; Fisher, C.; Bartek, J.; Dickson, C.; Barnes, D.; Peters, G. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res. 1994, 54, 1812-1817.
23. Keyomarsi, K.; Conte, D., Jr.; Toyofuku, W.; Fox, M.P. Deregulation of cyclin E in breast cancer. Oncogene 1995, 11, 941-950.
24. Shapiro, G.I.; Harper, J.W. Anticancer drug targets: Cell cycle and checkpoint control. J. Clin. Investig. 1999, 104, 1645-1653.
25. Gan, F.F.; Nagle, A.A.; Ang, X.; Ho, O.H.; Tan, S.H.; Yang, H.; Chui, W.K.; Chew, E.H. Shogaols at proapoptotic concentrations induce G(2)/M arrest and aberrant mitotic cell death associated with tubulin aggregation. Apoptosis 2011, 16, 856-867.
26. Wadhwa, R.; Singh, R.; Gao, R.; Shah, N.; Widodo, N.; Nakamoto, T.; Ishida, Y.; Terao, K.; Kaul, S.C. Water extract of ashwagandha leaves has anticancer activity: Identification of an active component and its mechanism of action. PLoS One 2013, 8, e77189.
27. Zhang, W.; Liu, H.T. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 2002, 12, 9-18.
28. Furlong, E.E.; Rein, T.; Martin, F. YY1 and NF1 both activate the human p53 promoter by alternatively binding to a composite element, and YY1 and E1A cooperate to amplify p53 promoter activity. Mol. Cell. Biol. 1996, 16, 5933-5945.
29. Omar, H.A.; Sargeant, A.M.; Weng, J.R.; Wang, D.; Kulp, S.K.; Patel, T.; Chen, C.S. Targeting of the Akt-nuclear factor-κB signaling network by [1-(4-chloro-3-nitrobenzenesulfonyl)-1Hindol-3-yl]-methanol (OSU-A9), a novel indole-3-carbinol derivative, in a mouse model of hepatocellular carcinoma. Mol. Pharmacol. 2009, 76, 957-968.
30. Rao, C.V.; Patlolla, J.M.; Qian, L.; Zhang, Y.; Brewer, M.; Mohammed, A.; Desai, D.; Amin, S.; Lightfoot, S.; Kopelovich, L. Chemopreventive effects of the p53-modulating agents CP-31398 and Prima-1 in tobacco carcinogen-induced lung tumorigenesis in A/J mice. Neoplasia 2013, 15, 1018-1027.
31. Weng, J.R.; Tsai, C.H.; Omar, H.A.; Sargeant, A.M.; Wang, D.; Kulp, S.K.; Shapiro, C.L.; Chen, C.S. OSU-A9, a potent indole-3-carbinol derivative, suppresses breast tumor growth by targeting the Akt-NF-κB pathway and stress response signaling. Carcinogenesis 2009, 30, 1702-1709.
32. Hung, J.H.; Teng, Y.N.; Wang, L.H.; Su, I.J.; Wang, C.C.; Huang, W.; Lee, K.H.; Lu, K.Y. Induction of Bcl-2 expression by hepatitis B virus pre-S2 mutant large surface protein resistance to 5-fluorouracil treatment in Huh-7 cells. PLoS One 2011, 6, e28977.
33. Omar, H.A.; Arafa El, S.A.; Salama, S.A.; Arab, H.H.; Wu, C.H.; Weng, J.R. OSU-A9 inhibits angiogenesis in human umbilical vein endothelial cells via disrupting Akt-NF-κB and MAPK signaling pathways. Toxicol. Appl. Pharmacol. 2013, 272, 616-624.
34. Reddy, A.S.; Zhang, S. Polypharmacology: Drug discovery for the future. Expert Rev. Clin. Pharmacol. 2013, 6, 41-47.
35. Ryan, K.M.; Phillips, A.C.; Vousden, K.H. Regulation and function of the p53 tumor suppressor protein. Curr. Opin. Cell Biol. 2001, 13, 332-337.
36. Chandel, N.S.; vander Heiden, M.G.; Thompson, C.B.; Schumacker, P.T. Redox regulation of p53 during hypoxia. Oncogene 2000, 19, 3840-3848.
37. Chang, B.D.; Xuan, Y.; Broude, E.V.; Zhu, H.; Schott, B.; Fang, J.; Roninson, I.B. Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene 1999, 18, 4808-4818.
38. Lin, W.C.; Chuang, Y.C.; Chang, Y.S.; Lai, M.D.; Teng, Y.N.; Su, I.J.; Wang, C.C.; Lee, K.H.; Hung, J.H. Endoplasmic reticulum stress stimulates p53 expression through NF-κB activation. PLoS One 2012, 7, e39120.
39. Wu, H.; Lozano, G. NF-kappa B activation of p53. A potential mechanism for suppressing cell growth in response to stress. J. Biol. Chem. 1994, 269, 20067-20074.
40. Ryan, K.M.; Ernst, M.K.; Rice, N.R.; Vousden, K.H. Role of NF-κB in p53-mediated programmed cell death. Nature 2000, 404, 892-897.
41. Meisse, D.; van de Casteele, M.; Beauloye, C.; Hainault, I.; Kefas, B.A.; Rider, M.H.; Foufelle, F.; Hue, L. Sustained activation of AMP-activated protein kinase induces c-Jun N-terminal kinase activation and apoptosis in liver cells. FEBS Lett. 2002, 526, 38-42.
42. Kefas, B.A.; Cai, Y.; Ling, Z.; Heimberg, H.; Hue, L.; Pipeleers, D.; van de Casteele, M. AMP-activated protein kinase can induce apoptosis of insulin-producing MIN6 cells through stimulation of c-Jun-N-terminal kinase. J. Mol. Endocrinol. 2003, 30, 151-161.
43. Igata, M.; Motoshima, H.; Tsuruzoe, K.; Kojima, K.; Matsumura, T.; Kondo, T.; Taguchi, T.; Nakamaru, K.; Yano, M.; Kukidome, D.; et al. Adenosine monophosphate-activated protein kinase suppresses vascular smooth muscle cell proliferation through the inhibition of cell cycle progression. Circulation Res. 2005, 97, 837-844.
44. Hickson-Bick, D.L.; Buja, L.M.; McMillin, J.B. Palmitate-mediated alterations in the fatty acid metabolism of rat neonatal cardiac myocytes. J. Mol. Cell. Cardiol. 2000, 32, 511-519.
45. Weng, J.R.; Bai, L.Y.; Omar, H.A.; Sargeant, A.M.; Yeh, C.T.; Chen, Y.Y.; Tsai, M.H.; Chiu, C.F. A novel indole-3-carbinol derivative inhibits the growth of human oral squamous cell carcinoma in vitro. Oral Oncol. 2010, 46, 748-754.